Skip to main content
Erschienen in: World Journal of Urology 6/2019

17.09.2018 | Original Article

The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade

verfasst von: Vincent Beck, Boris Schlenker, Annika Herlemann, Maria Apfelbeck, Alexander Buchner, Christian Gratzke, Christian G. Stief, Stefan Tritschler

Erschienen in: World Journal of Urology | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate changes in clinical data and pathological features of prostatectomy specimens of prostate cancer (PCa) patients in a large tertiary care center over the last 12 years as potential consequence of reduced acceptance of prostate-specific antigen (PSA)-based screening and implementation of active surveillance as a therapeutic option in PCa.

Methods

We retrospectively identified all patients with PCa who underwent radical prostatectomy at our institution between 2004 and 2016 from our clinical database. We reviewed clinical and pathological data including patient age, PSA level, number of positive cores and Gleason score in prostate biopsy, and pathologic N- and T-stage, and Gleason score in radical prostatectomy specimen.

Results

Data of 5497 consecutive patients were analyzed. Median PSA increased from 7 (IQR 4.8–10.5) to 9 ng/ml (IQR 5.8–16.1; p < 0.001), and median number of positive biopsy cores increased from 3 (IQR 2–5) to 5 (IQR 3–7; p < 0.001). The proportion of patients with Gleason score ≥ 7 in biopsy and prostatectomy specimens increased from 40 to 78% and 49 to 89% (p < 0.001), respectively. The rate of locally advanced (≥ pT3a) and lymph node-positive tumors increased from 28 to 43% and 5 to 16% (p < 0.001), respectively.

Conclusions

We observed a significant change in clinical and pathological findings in our prostatectomy series with a significantly higher proportion of aggressive and locally advanced PCa in recent years. These findings may be related to a reduced acceptance of PSA-based screening and the use of active surveillance as management strategy and have significant impact on daily patient care.
Literatur
1.
Zurück zum Zitat Andriole GL, Crawford ED, Grubb RL III et al (2012) Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104:125–132CrossRefPubMedPubMedCentral Andriole GL, Crawford ED, Grubb RL III et al (2012) Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104:125–132CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Boorjian SA, Karnes RJ, Viterbo R et al (2011) Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117:2883–2891CrossRefPubMed Boorjian SA, Karnes RJ, Viterbo R et al (2011) Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117:2883–2891CrossRefPubMed
3.
Zurück zum Zitat Budaus L, Isbarn H, Schlomm T et al (2009) Current technique of open intrafascial nerve-sparing retropubic prostatectomy. Eur Urol 56:317–324CrossRefPubMed Budaus L, Isbarn H, Schlomm T et al (2009) Current technique of open intrafascial nerve-sparing retropubic prostatectomy. Eur Urol 56:317–324CrossRefPubMed
4.
Zurück zum Zitat Budaus L, Spethmann J, Isbarn H et al (2011) Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int 108:1256–1261CrossRefPubMed Budaus L, Spethmann J, Isbarn H et al (2011) Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. BJU Int 108:1256–1261CrossRefPubMed
5.
Zurück zum Zitat Cooperberg MR, Lubeck DP, Mehta SS et al (2003) Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170:S21–S25 (discussion S26–S27) PubMed Cooperberg MR, Lubeck DP, Mehta SS et al (2003) Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170:S21–S25 (discussion S26–S27) PubMed
6.
Zurück zum Zitat Cooperberg MR, Vickers AJ, Broering JM et al (2010) Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116:5226–5234CrossRefPubMed Cooperberg MR, Vickers AJ, Broering JM et al (2010) Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116:5226–5234CrossRefPubMed
7.
Zurück zum Zitat De Oliveira C, Bremner KE, Pataky R et al (2013) Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. CMAJ Open 1:E151–E158CrossRefPubMedPubMedCentral De Oliveira C, Bremner KE, Pataky R et al (2013) Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. CMAJ Open 1:E151–E158CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Downer MK, Stampfer MJ, Cooperberg MR (2017) Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not?. JAMA Oncol 3:1623–1627CrossRefPubMed Downer MK, Stampfer MJ, Cooperberg MR (2017) Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not?. JAMA Oncol 3:1623–1627CrossRefPubMed
9.
Zurück zum Zitat Droz JP, Aapro M, Balducci L et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15:e404–e414CrossRefPubMed Droz JP, Aapro M, Balducci L et al (2014) Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 15:e404–e414CrossRefPubMed
10.
Zurück zum Zitat Eapen RS, Herlemann A, Washington SL III et al (2017) Impact of the United States Preventive Services Task Force ‘D’ recommendation on prostate cancer screening and staging. Curr Opin Urol 27:205–209CrossRefPubMed Eapen RS, Herlemann A, Washington SL III et al (2017) Impact of the United States Preventive Services Task Force ‘D’ recommendation on prostate cancer screening and staging. Curr Opin Urol 27:205–209CrossRefPubMed
11.
Zurück zum Zitat Farkas A, Schneider D, Perrotti M et al (1998) National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 52:444–448 (discussion 448–449) CrossRefPubMed Farkas A, Schneider D, Perrotti M et al (1998) National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 52:444–448 (discussion 448–449) CrossRefPubMed
12.
Zurück zum Zitat Gallina A, Chun FK, Suardi N et al (2008) Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 101:1513–1518CrossRefPubMed Gallina A, Chun FK, Suardi N et al (2008) Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int 101:1513–1518CrossRefPubMed
13.
Zurück zum Zitat Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64CrossRefPubMed Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58–64CrossRefPubMed
14.
Zurück zum Zitat Groeben C, Koch R, Baunacke M et al (2016) High volume is the key for improving in-hospital outcomes after radical prostatectomy: a total population analysis in Germany from 2006 to 2013. World J Urol 7:1045–1053 Groeben C, Koch R, Baunacke M et al (2016) High volume is the key for improving in-hospital outcomes after radical prostatectomy: a total population analysis in Germany from 2006 to 2013. World J Urol 7:1045–1053
15.
Zurück zum Zitat Hager B, Kraywinkel K, Keck B et al (2017) Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer Prostatic Dis 20:61–66CrossRefPubMed Hager B, Kraywinkel K, Keck B et al (2017) Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. Prostate Cancer Prostatic Dis 20:61–66CrossRefPubMed
16.
Zurück zum Zitat Hatiboglu G, Teber D, Tichy D et al (2016) Predictive factors for immediate continence after radical prostatectomy. World J Urol 34:113–120CrossRefPubMed Hatiboglu G, Teber D, Tichy D et al (2016) Predictive factors for immediate continence after radical prostatectomy. World J Urol 34:113–120CrossRefPubMed
17.
Zurück zum Zitat Herlemann A, Buchner A, Kretschmer A et al (2017) Postoperative upgrading of prostate cancer in men > 75 years: a propensity score-matched analysis. World J Urol 35:1517–1524CrossRefPubMed Herlemann A, Buchner A, Kretschmer A et al (2017) Postoperative upgrading of prostate cancer in men > 75 years: a propensity score-matched analysis. World J Urol 35:1517–1524CrossRefPubMed
18.
Zurück zum Zitat Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272–277CrossRefPubMed Klotz L, Vesprini D, Sethukavalan P et al (2015) Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33:272–277CrossRefPubMed
19.
Zurück zum Zitat Labrie F, Candas B, Cusan L et al (2004) Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59:311–318CrossRefPubMed Labrie F, Candas B, Cusan L et al (2004) Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59:311–318CrossRefPubMed
20.
21.
Zurück zum Zitat Mandel P, Graefen M, Michl U et al (2015) The effect of age on functional outcomes after radical prostatectomy. Urol Oncol 33(203):e208–e211 Mandel P, Graefen M, Michl U et al (2015) The effect of age on functional outcomes after radical prostatectomy. Urol Oncol 33(203):e208–e211
22.
Zurück zum Zitat Mandel P, Kriegmair MC, Kamphake JK et al (2016) Tumor characteristics and oncologic outcome after radical prostatectomy in men 75 years old or older. J Urol 196:89–94CrossRefPubMed Mandel P, Kriegmair MC, Kamphake JK et al (2016) Tumor characteristics and oncologic outcome after radical prostatectomy in men 75 years old or older. J Urol 196:89–94CrossRefPubMed
23.
Zurück zum Zitat Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Montorsi F, Saad F, Briganti A, Steuber T, Budäus L, Huland H, Graefen M, Tilki D, Karakiewicz PI (2018) Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. Urol Oncol 36(8):365.e1–365.e7. https://doi.org/10.1016/j.urolonc.2018.05.019 CrossRef Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Montorsi F, Saad F, Briganti A, Steuber T, Budäus L, Huland H, Graefen M, Tilki D, Karakiewicz PI (2018) Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. Urol Oncol 36(8):365.e1–365.e7. https://​doi.​org/​10.​1016/​j.​urolonc.​2018.​05.​019 CrossRef
24.
Zurück zum Zitat Reese AC, Wessel SR, Fisher SG et al (2016) Evidence of prostate cancer “reverse stage migration” toward more advanced disease at diagnosis: data from the Pennsylvania Cancer Registry. Urol Oncol 34(335):e321–e338 Reese AC, Wessel SR, Fisher SG et al (2016) Evidence of prostate cancer “reverse stage migration” toward more advanced disease at diagnosis: data from the Pennsylvania Cancer Registry. Urol Oncol 34(335):e321–e338
25.
Zurück zum Zitat Ross JS, Wang R, Long JB et al (2012) Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med 172:1601–1603CrossRefPubMedPubMedCentral Ross JS, Wang R, Long JB et al (2012) Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med 172:1601–1603CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, Li M, Schultze-Seemann W, Ilhan H, Fendler WP, Bartenstein P, Grosu AL, Ganswindt U, Belka C, Meyer PT, Zamboglou C (2018) Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis. J Nucl Med. https://doi.org/10.2967/jnumed.118.212563 Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, Li M, Schultze-Seemann W, Ilhan H, Fendler WP, Bartenstein P, Grosu AL, Ganswindt U, Belka C, Meyer PT, Zamboglou C (2018) Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis. J Nucl Med. https://​doi.​org/​10.​2967/​jnumed.​118.​212563
28.
Zurück zum Zitat Schroder FH, Hugosson J, Roobol MJ et al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035CrossRefPubMedPubMedCentral Schroder FH, Hugosson J, Roobol MJ et al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Sooriakumaran P, Nyberg T, Akre O et al (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 348:g1502CrossRefPubMedPubMedCentral Sooriakumaran P, Nyberg T, Akre O et al (2014) Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ 348:g1502CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Wallner LP, Hsu JW, Loo RK et al (2015) Trends in prostate-specific antigen screening, prostate biopsies, urology visits, and prostate cancer treatments from 2000 to 2012. Urology 86:498–505CrossRefPubMed Wallner LP, Hsu JW, Loo RK et al (2015) Trends in prostate-specific antigen screening, prostate biopsies, urology visits, and prostate cancer treatments from 2000 to 2012. Urology 86:498–505CrossRefPubMed
33.
Zurück zum Zitat Zaffuto E, Gandaglia G, Fossati N et al (2017) Early postoperative radiotherapy is associated with worse functional outcomes in patients with prostate cancer. J Urol 197:669–675CrossRefPubMed Zaffuto E, Gandaglia G, Fossati N et al (2017) Early postoperative radiotherapy is associated with worse functional outcomes in patients with prostate cancer. J Urol 197:669–675CrossRefPubMed
34.
Zurück zum Zitat Zelefsky MJ, Eastham JA, Cronin AM et al (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28:1508–1513CrossRefPubMedPubMedCentral Zelefsky MJ, Eastham JA, Cronin AM et al (2010) Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 28:1508–1513CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Zeliadt SB, Hoffman RM, Etzioni R et al (2011) Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 103:520–523CrossRefPubMed Zeliadt SB, Hoffman RM, Etzioni R et al (2011) Influence of publication of US and European prostate cancer screening trials on PSA testing practices. J Natl Cancer Inst 103:520–523CrossRefPubMed
Metadaten
Titel
The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade
verfasst von
Vincent Beck
Boris Schlenker
Annika Herlemann
Maria Apfelbeck
Alexander Buchner
Christian Gratzke
Christian G. Stief
Stefan Tritschler
Publikationsdatum
17.09.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 6/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-018-2487-0

Weitere Artikel der Ausgabe 6/2019

World Journal of Urology 6/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.